Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Feb. 02, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted

Related Keywords

Cambridge , Cambridgeshire , United Kingdom , San Francisco , California , United States , Massachusetts , Geoffrey Mogilner , Olema Pharmaceuticals Inc , Compensation Committee Of Olema Board Directors , Nasdaq , Compensation Committee , Nasdaq Listing Rule , Olema Pharmaceuticals , Vice President , Investor Relations , Region ,